Together, these findings suggest that Ror2 plays a central role in influencing the ccRCC phenotype, and can be considered as a negative prognostic biomarker and potential therapeutic target in this cancer. This evidence concerns the gene ROR2 and nonpapillary renal cell carcinoma.